Persistence ofDNMT3AR882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Persistence ofDNMT3AR882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia

Published:2016-08-01 Issue:2 Volume:175 Page:226-236
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bhatnagar Bhavana¹²,Eisfeld Ann-Kathrin²,Nicolet Deedra²³,Mrózek Krzysztof²,Blachly James S.¹,Orwick Shelley¹²,Lucas David M.¹,Kohlschmidt Jessica²³,Blum William¹,Kolitz Jonathan E.⁴,Stone Richard M.⁵,Bloomfield Clara D.¹²,Byrd John C.¹²

Affiliation:

1. Division of Hematology; Department of Internal Medicine; The Ohio State University Comprehensive Cancer Center; Columbus OH USA

2. The Ohio State University Comprehensive Cancer Center; Columbus OH USA

3. Alliance for Clinical Trials in Oncology Statistics and Data Center; Mayo Clinic; Rochester MN USA

4. Monter Cancer Center; Hofstra North Shore-Long Island Jewish School of Medicine; Lake Success NY USA

5. Dana-Farber Cancer Institute; Boston MA USA

Funder

National Institutes of Health

Coleman Leukemia Research Foundation

Pelotonia Fellowship Program

D Warren Brown Foundation

NCCN Foundation

The Ohio Supercomputer Center

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14254/fullpdf

Reference44 articles.

1. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502;Attar;Journal of Clinical Oncology,2013

2. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720;Baer;Blood,2002

3. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia (AML) in first remission: a phase II Cancer and Leukemia Group B study (CALGB 10503, Alliance) [abstract];Blum;Blood,2012

4. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461);Byrd;Blood,2002

5. Dnmt3a is essential for hematopoietic stem cell differentiation;Challen;Nature Genetics,2012

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of Cell Type-Specific Effects of DNMT3A Mutations on Relapse in Acute Myeloid Leukemia;Molecules and Cells;2023-10

2. Clonal hematopoiesis and acute myeloid leukemia;Oncohematology;2023-09-12

3. The present and future of measurable residual disease testing in acute myeloid leukemia;Haematologica;2022-12-01

4. Revealing the Mysteries of Acute Myeloid Leukemia: From Quantitative PCR through Next-Generation Sequencing and Systemic Metabolomic Profiling;Journal of Clinical Medicine;2022-01-18

5. Differentiation therapy for myeloid malignancies: beyond cytotoxicity;Blood Cancer Journal;2021-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3